Repligen RGEN 深 沪
已收盘 09-26 16:00:00 美东时间
125.61
+3.930
+3.23%
华盛通- 最 高125.925
- 今 开122.00
- 成交量 56.31万股
- 最 低 121.99
- 昨 收 121.68
- 总市值 70.67亿
- 52周最高 182.52
- 市盈率 静 --
- 换手率 1.00%
- 52周最低 102.965
- 委 比 -76.88%
- 总股本 5625.76万
- 历史最高 327.32
- 量 比 0.67
- 振 幅 3.23%
- 历史最低 2.90
- 每 手 1
- 风险率 23.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Regenera Inc. Completes Private Placement to Bolster Financial Flexibility
Delta Cleantech ( ($TSE:RGEN) ) has shared an update. Regenera Inc. has success...
09-26 01:37
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
Evercore ISI Group Upgrades Repligen to Outperform, Raises Price Target to $155
Evercore ISI Group analyst Daniel Markowitz upgrades Repligen (NASDAQ:RGEN) from In-Line to Outperform and raises the price target from $130 to $155.
09-22 19:33
Repligen (RGEN) Receives a Buy from Craig-Hallum
In a report released on September 19, Matt Hewitt from Craig-Hallum reiterated ...
09-21 16:25
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
Jefferies Maintains Hold on Repligen, Lowers Price Target to $135
Jefferies analyst Matthew Stanton maintains Repligen (NASDAQ:RGEN) with a Hold and lowers the price target from $145 to $135.
09-12 18:20
Jefferies Remains a Hold on Repligen (RGEN)
Jefferies analyst Matthew Stanton, CFA maintained a Hold rating on Repligen tod...
09-12 07:25
HC Wainwright & Co. Reiterates Buy on Repligen, Maintains $180 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Repligen (NASDAQ:RGEN) with a Buy and maintains $180 price target.
09-03 18:49
Recursion to Participate in Upcoming Investor Conferences
Re: Recursion's Participation in Upcoming Investor Conferences Recursion (NASDAQ: RXRX), a clinical stage TechBio company, announced its participation in the following investor conferences: - Citi 2025 BioPharma Back to School Conference – September 3, 2025 - Morgan Stanley 23rd Annual Global Healthcare Conference – September 8, 2025 Webcasts will be available on the Recursion Investor Relations website (ir.recursion.com). Recursion leverage...
08-27 12:00
Repligen Corporation to Present at Upcoming September Conferences
Repligen Corporation will attend three investor conferences in September 2025. Olivier Loeillot, CEO, will participate in discussions at the Wells Fargo Healthcare Conference on September 4 in Boston and at the Bank of America Global Healthcare Conference on September 25 in London. Jason Garland, CFO, will attend 1x1 meetings at the Deutsche Bank Healthcare Summit on September 10 in New York. Live webcasts will be available via Repligen’s Investo...
08-22 11:30
